A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells

Leukemia Research

Volumn 25, Issue 1, 2001, Pages 77-83

  Takahashi, Ryoichi ^a   Shimazaki, Chihiro ^a   Inaba, Tohru ^a   Okano, Akira ^a   Hatsuse, Mayumi ^a   Okamoto, Akio ^a   Hirai, Hideyo ^a   Ashihara, Eishi ^a   Nakagawa, Masao ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Apoptosis; Bisphosphonate; Myeloma; YM529

Indexed keywords

1 HYDROXY 2 (IMIDAZO[1,2 A]PYRIDIN 3 YL)ETHANE 1,1 BISPHOSPHONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; INCADRONIC ACID; MINODRONIC ACID; PAMIDRONIC ACID; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; DOSE RESPONSE; DRUG POTENCY; HUMAN; HUMAN CELL; MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; DIPHOSPHONATES; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; MULTIPLE MYELOMA; TUMOR CELLS, CULTURED;

EID: 0035179684     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00087-4     Document Type: Article

References (30)

1. Bone destruction and hypercalcemia in plasma cell myeloma
2. Plasma cell myeloma - New biological insights and advances in therapy
3. Bisphosphonate: A new class of drugs in diseases of bone and calcium metabolism
4. Diphosphonates and Page's disease of bone
5. Efficacy of the bisphosphonate APD in the control of Paget's bone disease
6. Bisphosphonates in multiple myeloma
7. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study
8. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)
9. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
10. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
11. Anti-myeloma activity of pamidronate in vivo
12. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
13. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
14. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway
15. Sensitive determination of a novel bisphosphonate, YM529, in plasma, urine and bone by high-performance liquid chromatography with fluorescence detection
16. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice
17. Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism
18. 3H]-thymidine incorporation assay
19. A rapid single-laser flow cytometric method for discrimination of early apoptotic cells in a heterogenous cell population
20. Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes
21. Pamidronate inhibits growth of myeloma in vivo in the SCID-hu system
22. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro
23. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment
24. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
25. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
26. Ibandronate reduces osteolytic leisions but not tumor burden in a murine model of myeloma bone disease
27. Studies on novel bone resorption inhibitors. II. Synthesis and pharmacologicalactivities of fused aza-heteroarylbisphosphonate derivatives
28. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure
29. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis
30. Excessive bone resorption in human plasmacytomas: Direct induction by tumour cells in vivo